Literature DB >> 8569442

Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.

C W Jung1.   

Abstract

The surface properties of the active ingredients in AMI colloidal, superparamagnetic iron oxide magnetic resonance (MR) contrast agents are described. Scanning electron microscopy/energy dispersive X-ray elemental analyses and diffuse reflectance Fourier transform infrared spectroscopy (FTIR) spectra of ferumoxsil (AMI-121 drug substance) were consistent with the presence of a monolayer of H2NCH2CH2NHCH2CH2CH2Si(O-)3 siloxane monomer or dimer. The X-ray photoelectron spectra (XPS) of ferumoxsil are also consistent with complete coverage of the iron oxide surface with a monolayer of siloxane. The static secondary ion mass spectra (SSIMS) of ferumoxsil showed that the siloxane film is covalently bonded (i.e., Si-O-Fe bonds) to the iron oxide surface. The FTIR of ferumoxides (AMI-25) and Ferumoxtran (AMI-227) showed only adsorbed dextran. The XPS spectra of the dextran-coated colloids showed that Ferumoxtran has a thicker layer of dextran than ferumoxides iron oxide particles (approximately 5 and approximately 3 nm, respectively). The SSIMS spectra of these dextran-coated colloids showed only low mass fragments due to the adsorbed dextran. The nature of the interactions of the dextran coating with the iron oxide surfaces of ferumoxides and Ferumoxtran is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569442     DOI: 10.1016/0730-725x(95)00023-a

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  54 in total

Review 1.  Imaging the lymphatic system: possibilities and clinical applications.

Authors:  Olivier Clément; Alain Luciani
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

2.  Combined off-resonance imaging and T2 relaxation in the rotating frame for positive contrast MR imaging of infection in a murine burn model.

Authors:  Ovidiu C Andronesi; Dionyssios Mintzopoulos; Valeria Righi; Nikolaos Psychogios; Meenu Kesarwani; Jianxin He; Shingo Yasuhara; George Dai; Laurence G Rahme; Aria A Tzika
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

3.  In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.

Authors:  Heike E Daldrup-Link; Reinhardt Meier; Martina Rudelius; Guido Piontek; Morand Piert; Stephan Metz; Marcus Settles; Christoph Uherek; Winfried Wels; Jürgen Schlegel; Ernst J Rummeny
Journal:  Eur Radiol       Date:  2004-12-23       Impact factor: 5.315

Review 4.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

Review 5.  Multifunctional magnetic nanoparticles for targeted imaging and therapy.

Authors:  Jason R McCarthy; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

6.  Labelling of mammalian cells for visualisation by MRI.

Authors:  Monique R Bernsen; Amber D Moelker; Piotr A Wielopolski; Sandra T van Tiel; Gabriel P Krestin
Journal:  Eur Radiol       Date:  2009-08-12       Impact factor: 5.315

7.  Tracking and Quantification of Magnetically Labeled Stem Cells using Magnetic Resonance Imaging.

Authors:  Forrest Goodfellow; Gregory A Simchick; Luke J Mortensen; Steven L Stice; Qun Zhao
Journal:  Adv Funct Mater       Date:  2016-02-17       Impact factor: 18.808

Review 8.  Noninvasive cell-tracking methods.

Authors:  Moritz F Kircher; Sanjiv S Gambhir; Jan Grimm
Journal:  Nat Rev Clin Oncol       Date:  2011-09-27       Impact factor: 66.675

9.  Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model.

Authors:  Ahmet Erten; Wolf Wrasidlo; Miriam Scadeng; Sadik Esener; Robert M Hoffman; Michael Bouvet; Milan Makale
Journal:  Nanomedicine       Date:  2010-07-03       Impact factor: 5.307

10.  Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro.

Authors:  Stephan Metz; Gabriel Bonaterra; Martina Rudelius; Marcus Settles; Ernst J Rummeny; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2004-07-13       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.